Effect of type 2 diabetes medications on fracture risk

Type 2 diabetes, one of the most frequent chronic diseases, has an important effect on bone metabolism, with most studies reporting an increased prevalence of fractures in these patients despite an apparently increased bone mineral density. Most probable explanation is an alteration of bone structur...

Full description

Saved in:
Bibliographic Details
Published in:Annals of translational medicine 2019-10, Vol.7 (20), p.580-580
Main Authors: Guja, Cristian, Guja, Loreta, Miulescu, Rucsandra Dănciulescu
Format: Article
Language:English
Subjects:
Review
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c323t-6c8a82a0f8b7ce989403c5241ed264bedc958e9e53e50b5c157f3ba13305a273
cites
container_end_page 580
container_issue 20
container_start_page 580
container_title Annals of translational medicine
container_volume 7
creator Guja, Cristian
Guja, Loreta
Miulescu, Rucsandra Dănciulescu
description Type 2 diabetes, one of the most frequent chronic diseases, has an important effect on bone metabolism, with most studies reporting an increased prevalence of fractures in these patients despite an apparently increased bone mineral density. Most probable explanation is an alteration of bone structure/quality with increased fragility but the different diabetes medications influence the risk of fracture. While metformin and incretin-based therapies are safe, thiazolidinediones and canagliflozin (sodium-glucose cotransporter-2 inhibitor) negatively impact bone metabolism and should be avoided in subjects at increased risk of fractures. Insulin and sulphonylureas are generally safe but can increase the risk of hypoglycemia and falls with subsequent traumatic fractures. Their combination should be avoided, especially in elderly subjects.
doi_str_mv 10.21037/atm.2019.09.51
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6861738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2322738934</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-6c8a82a0f8b7ce989403c5241ed264bedc958e9e53e50b5c157f3ba13305a273</originalsourceid><addsrcrecordid>eNpVkEtPwzAQhC0EolXpmRvykUtSP-LEviChqjykSlx6txxnDYE8iu0g9d8TaKnKaVfa2ZnRh9A1JSmjhBcLE9uUEapSolJBz9CUcSISIbk6P9knaB7COyGEMqo4IZdowqkkhcjpFOUr58BG3Dscd1vADFe1KSFCwC1UtTWx7ruA-w47b2wcPGBfh48rdOFME2B-mDO0eVhtlk_J-uXxeXm_TixnPCa5lUYyQ5wsCwtKqoxwK1hGoWJ5VkJllZCgQHAQpBSWisLx0lA-djes4DN0t7fdDuVYx0IXvWn01tet8Tvdm1r_v3T1m37tv3Quc1pwORrcHgx8_zlAiLqtg4WmMR30Q9CMszFGKp6N0sVean0fggd3jKFE__LWI2_9w1sTpQUdP25O2x31f3T5N56Ce38</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2322738934</pqid></control><display><type>article</type><title>Effect of type 2 diabetes medications on fracture risk</title><source>PubMed Central</source><creator>Guja, Cristian ; Guja, Loreta ; Miulescu, Rucsandra Dănciulescu</creator><creatorcontrib>Guja, Cristian ; Guja, Loreta ; Miulescu, Rucsandra Dănciulescu</creatorcontrib><description>Type 2 diabetes, one of the most frequent chronic diseases, has an important effect on bone metabolism, with most studies reporting an increased prevalence of fractures in these patients despite an apparently increased bone mineral density. Most probable explanation is an alteration of bone structure/quality with increased fragility but the different diabetes medications influence the risk of fracture. While metformin and incretin-based therapies are safe, thiazolidinediones and canagliflozin (sodium-glucose cotransporter-2 inhibitor) negatively impact bone metabolism and should be avoided in subjects at increased risk of fractures. Insulin and sulphonylureas are generally safe but can increase the risk of hypoglycemia and falls with subsequent traumatic fractures. Their combination should be avoided, especially in elderly subjects.</description><identifier>ISSN: 2305-5839</identifier><identifier>EISSN: 2305-5839</identifier><identifier>DOI: 10.21037/atm.2019.09.51</identifier><identifier>PMID: 31807561</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Review</subject><ispartof>Annals of translational medicine, 2019-10, Vol.7 (20), p.580-580</ispartof><rights>2019 Annals of Translational Medicine. All rights reserved.</rights><rights>2019 Annals of Translational Medicine. All rights reserved. 2019 Annals of Translational Medicine.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c323t-6c8a82a0f8b7ce989403c5241ed264bedc958e9e53e50b5c157f3ba13305a273</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861738/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861738/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31807561$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guja, Cristian</creatorcontrib><creatorcontrib>Guja, Loreta</creatorcontrib><creatorcontrib>Miulescu, Rucsandra Dănciulescu</creatorcontrib><title>Effect of type 2 diabetes medications on fracture risk</title><title>Annals of translational medicine</title><addtitle>Ann Transl Med</addtitle><description>Type 2 diabetes, one of the most frequent chronic diseases, has an important effect on bone metabolism, with most studies reporting an increased prevalence of fractures in these patients despite an apparently increased bone mineral density. Most probable explanation is an alteration of bone structure/quality with increased fragility but the different diabetes medications influence the risk of fracture. While metformin and incretin-based therapies are safe, thiazolidinediones and canagliflozin (sodium-glucose cotransporter-2 inhibitor) negatively impact bone metabolism and should be avoided in subjects at increased risk of fractures. Insulin and sulphonylureas are generally safe but can increase the risk of hypoglycemia and falls with subsequent traumatic fractures. Their combination should be avoided, especially in elderly subjects.</description><subject>Review</subject><issn>2305-5839</issn><issn>2305-5839</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkEtPwzAQhC0EolXpmRvykUtSP-LEviChqjykSlx6txxnDYE8iu0g9d8TaKnKaVfa2ZnRh9A1JSmjhBcLE9uUEapSolJBz9CUcSISIbk6P9knaB7COyGEMqo4IZdowqkkhcjpFOUr58BG3Dscd1vADFe1KSFCwC1UtTWx7ruA-w47b2wcPGBfh48rdOFME2B-mDO0eVhtlk_J-uXxeXm_TixnPCa5lUYyQ5wsCwtKqoxwK1hGoWJ5VkJllZCgQHAQpBSWisLx0lA-djes4DN0t7fdDuVYx0IXvWn01tet8Tvdm1r_v3T1m37tv3Quc1pwORrcHgx8_zlAiLqtg4WmMR30Q9CMszFGKp6N0sVean0fggd3jKFE__LWI2_9w1sTpQUdP25O2x31f3T5N56Ce38</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Guja, Cristian</creator><creator>Guja, Loreta</creator><creator>Miulescu, Rucsandra Dănciulescu</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201910</creationdate><title>Effect of type 2 diabetes medications on fracture risk</title><author>Guja, Cristian ; Guja, Loreta ; Miulescu, Rucsandra Dănciulescu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-6c8a82a0f8b7ce989403c5241ed264bedc958e9e53e50b5c157f3ba13305a273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Review</topic><toplevel>online_resources</toplevel><creatorcontrib>Guja, Cristian</creatorcontrib><creatorcontrib>Guja, Loreta</creatorcontrib><creatorcontrib>Miulescu, Rucsandra Dănciulescu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guja, Cristian</au><au>Guja, Loreta</au><au>Miulescu, Rucsandra Dănciulescu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of type 2 diabetes medications on fracture risk</atitle><jtitle>Annals of translational medicine</jtitle><addtitle>Ann Transl Med</addtitle><date>2019-10</date><risdate>2019</risdate><volume>7</volume><issue>20</issue><spage>580</spage><epage>580</epage><pages>580-580</pages><issn>2305-5839</issn><eissn>2305-5839</eissn><abstract>Type 2 diabetes, one of the most frequent chronic diseases, has an important effect on bone metabolism, with most studies reporting an increased prevalence of fractures in these patients despite an apparently increased bone mineral density. Most probable explanation is an alteration of bone structure/quality with increased fragility but the different diabetes medications influence the risk of fracture. While metformin and incretin-based therapies are safe, thiazolidinediones and canagliflozin (sodium-glucose cotransporter-2 inhibitor) negatively impact bone metabolism and should be avoided in subjects at increased risk of fractures. Insulin and sulphonylureas are generally safe but can increase the risk of hypoglycemia and falls with subsequent traumatic fractures. Their combination should be avoided, especially in elderly subjects.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>31807561</pmid><doi>10.21037/atm.2019.09.51</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2305-5839
ispartof Annals of translational medicine, 2019-10, Vol.7 (20), p.580-580
issn 2305-5839
2305-5839
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6861738
source PubMed Central
subjects Review
title Effect of type 2 diabetes medications on fracture risk
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A01%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20type%202%20diabetes%20medications%20on%20fracture%20risk&rft.jtitle=Annals%20of%20translational%20medicine&rft.au=Guja,%20Cristian&rft.date=2019-10&rft.volume=7&rft.issue=20&rft.spage=580&rft.epage=580&rft.pages=580-580&rft.issn=2305-5839&rft.eissn=2305-5839&rft_id=info:doi/10.21037/atm.2019.09.51&rft_dat=%3Cproquest_pubme%3E2322738934%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c323t-6c8a82a0f8b7ce989403c5241ed264bedc958e9e53e50b5c157f3ba13305a273%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2322738934&rft_id=info:pmid/31807561&rfr_iscdi=true